Nicholas J. Vogelzang - Published Works

Published Works

• Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, Demarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA; Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial Lancet Oncol. 2012 Jul 13. (epub ahead of print)

• Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn Dl, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato III SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE; Multicenter, Double-Blind Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. 2012 June 4. (e-pub ahead of print)

• Smith DC, Tangen CM, Hussain MHA, Van Veldhuizen, Jr PJ, Hartner GW, Stuart RK, Mills GM, Vogelzang NJ, Thompson IM. Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate. Southwest Oncology Group (SWOG) S0032 Urology 2011 Feb 18

• Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff DD, Kawabe T, Sharma S: Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid tumors. Clinical Cancer Res. 2011 January 10. (e-pub ahead of print)

• Galsky MD, Hahn NM, Rosenberg J, Sonpavde S, Hutson T, Oh W, Dreicer R, Vogelzang NJ, Sternberg C, Bajorin D, Bellmunt D. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. Journal of Clinical Oncology 2011 (IN PRESS)

• Dorff TB, Flaig TW, Tangen C, Hussain M, Swanson GP, Wood, DP, Sakr W, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson I, Glode LM. “Adjuvant Androgen Deprivation for High Risk Prostate Cancer after Radical Prostatectomy: Southwest Oncology Group (SWOG) Study S9921”. Journal of Clinical Oncology 2010 322776 (IN PRESS)

• Kris MG, Benowitz SI, Adams. S, Diller L, Ganz P, Kahlenberg MS, Le QT, Markman M, Masters GA, Newman L, Obel JC, Seidman AD, Smith SM, Vogelzang NJ, Petrelli NJ: Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2010 December 20;28(36):5327-47,. No abstract available

• Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, Paz L, May, Ward DC, Vogelzang NJ, Fink LM. Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer. Am J Clin Pathol. 2010 Dec;134(6):964-969.PMID 21088161

• Vogelzang NJ. Another Step Toward the Cure of Metastatic Renal Cell Carcinoma? J Clin Oncol. 2010 Oct 25.

• Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; for Cancer and Leukemia Group B. A phase 2 study of estramustine, docetaxel, and bbevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2010 Sep 22.

• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V,Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116(18):4256-65.PMID 20549832

• Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Lancet Oncol. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. 2010 May 25.

• Galsky MD, Vogelzang NJ. Ann Oncol. Docetaxel-based combination therapy for castration-resistant prostate cancer. 2010 Mar 29.